Clinical trials: Pancreatic Fibrosis
Neuroendocrine Carcinoma of Pancreas, Duodenum Carcinoma
Preoperative Radiotherapy in Patients at High Risk of Postoperative Pancreatic Fistula After Pancreatoduodenectomy
The FIBROPANC-1 investigates the feasibility and safety of preoperative stereotactic radiotherapy of 4cm pancreas in patients undergoing pancreatoduodenectomy at high risk (>25%) of developing post operative pancreatic fistula…
- Conditions
- Neuroendocrine Carcinoma of Pancreas, Duodenum Carcinoma, Pancreas Neoplasm, Distal Cholangiocarcinoma
- Trial name
- FIBROPANC-1 (NCT05641233)
- Testing
- Stereotactic radiotherapy
- Where
- 2 sites in Netherlands
- Volunteers
- 33 people
- Sponsor
- Erasmus Medical Center
Cystic Fibrosis
Growth Hormone Treatment Study in Children With Cystic Fibrosis
Cystic fibrosis (CF) is a catabolic condition, and children affected with this disease frequently have problems with growth, despite adequate nutrition.
- Trial name
- NCT00256555
- Testing
- Nutropin AQ
- Sponsor
- University of Texas Southwestern Medical Center
Emphysema, Chronic Obstructive Pulmonary Disease (COPD)
Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability
The purpose of this research study is to learn about the safety of transplanting lungs obtained from non-heart-beating donors (NHBDs) that have been ventilated (attached to a breathing machine or ventilator to deliver oxygen) and…
- Conditions
- Emphysema, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis, Pulmonary Fibrosis
- Trial name
- NCT01615484
- Testing
- Transplantation of lungs obtained from Non-Heart-Beating Donors (NHBDs) after ex-vivo perfusion w/ STEEN Solution™, STEEN Solution™
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- University of North Carolina, Chapel Hill
Exocrine Pancreatic Insufficiency (EPI), Cystic Fibrosis (CF)
Phase 2 Study to Assess the Safety and Efficacy of ANG003
In this study, ANG003, a pancreatic enzyme replacement therapy (PERT; commonly called "enzymes"), is being investigated as a potential treatment for exocrine pancreatic insufficiency (EPI).
- Trial name
- NCT07450547
- Testing
- ANG003 Dose A, ANG003 Dose B, Creon
- Where
- 28 sites in United States
- Volunteers
- 113 people
- Sponsor
- Anagram Therapeutics, Inc.
Cystic Fibrosis (CF)
Impact of Elexacaftor-Tezacaftor-Ivacaftor Treatment on Metabolic, Epigenetic and Fecal Microbiota Profiles in People With Cystic Fibrosis.
Cystic Fibrosis (CF) is a genetic disease that affects multiple organs and systems. In recent years, the marketing of CFTR protein modulator drugs, such as the Elexacaftor-Tezacaftor-Ivacaftor (ETI) combination, has significantly…
- Trial name
- NCT07363304
- Testing
- Elexacaftor, Tezacaftor, Ivacaftor
- Where
- 6 sites in Italy
- Volunteers
- 150 people
- Sponsor
- Meyer Children's Hospital IRCCS
Cystic Fibrosis, Hepatitis A
Hepatitis B in Cystic Fibrosis and Latent Tuberculosis Respectively
CF patients are at risk for hepatic disease. Vaccination is recommended to all CF patients according to European consensus. The aim of the study is to vaccinate as many patients as possible and to follow up whether immunization…
- Conditions
- Cystic Fibrosis, Hepatitis A, Hepatitis B, Tuberculosis
- Trial name
- NCT02605538
- Testing
- Vaccination with vaccine against hepatitis A and B
- Where
- Sweden
- Volunteers
- healthy volunteers welcome
- Sponsor
- Karolinska University Hospital
Cystic Fibrosis (CF)
: TRANSITION: An Observational Study of Transition From Lumacaftor/Ivacaftor to Tezacaftor/Ivacaftor (Tez/Iva)
This study is a single center study of clinical and laboratory outcomes in patients ≥ 12 who transition from use of Orkambi to tez/iva.
- Trial name
- NCT03445793
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Jewish Health
Cystic Fibrosis
Impact of the Introduction of ORKAMBI on Anxiety, Depression, Quality of Life and Adherence of Adolescents and Young Adults
The aim of this project is to evaluate the psychological reshuffle induced by ORKAMBI. The particular focus of this study is the consequence of its introduction on anxiety, depression, quality of life and adherence to all cystic…
- Trial name
- ORK-AJA (NCT03659214)
- Testing
- Questionnaires
- Where
- France
- Volunteers
- 19 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Cystic Fibrosis
Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del
This is a Phase 3, 2-part (Part A and Part B), open-label, multicenter study evaluating the pharmacokinetics (PK), safety, tolerability, and pharmacodynamics (PD) of multiple doses of lumacaftor/ivacaftor (LUM/IVA) in subjects 2…
- Trial name
- NCT02797132
- Testing
- LUM/IVA
- Where
- 20 sites in United States, Canada
- Volunteers
- 62 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Cystic Fibrosis, Hirschprung's Disease
Evaluating the Alimentary and Respiratory Tracts in Health and Disease (EARTH) Research Program.
The investigators have established the "Evaluating the Alimentary and Respiratory Tracts in Health and disease" (EARTH) research program.
- Conditions
- Cystic Fibrosis, Hirschprung's Disease, Obstructive Sleep Apnea, Healthy
- Trial name
- EARTH (NCT04071314)
- Where
- Australia
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- The University of New South Wales
Cystic Fibrosis, Pulmonary Exacerbation
Cystic Fibrosis (CF) Leukocyte Genes as Biomarkers for Novel Therapies
Presently, effectiveness of treatments for CF lung disease is judged by improvement in lung function (FEV1). However, in CF patients, FEV1 can range from severely decreased to normal, and improvements may occur slowly.
- Trial name
- NCT00727285
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Jewish Health
Cystic Fibrosis
Bottle PEP in Cystic Fibrosis
The study aims to investigate the sustainability of Bottle-PEP in patients with cystic fibrosis
- Trial name
- NCT04961008
- Testing
- Bottle-PEP, Routine physiotherapy
- Where
- Turkey (Türkiye)
- Volunteers
- 34 people
- Sponsor
- Marmara University
Asthma, Bronchiectasis
Lung Clearance Index (LCI) in Pediatric Patients With Obstructive Lung Disease
Chronic respiratory diseases (CRDs) affect the airways and other structures of the lungs and thereby lead to ventilation inhomogeneity. The most common CRDs in children are asthma, bronchiectasis and cystic fibrosis (CF).
- Conditions
- Asthma, Bronchiectasis, Cystic Fibrosis
- Trial name
- NCT02950116
- Testing
- Perform three multiple breath nitrogen washout tests (N2-MBW-test)
- Where
- Belgium
- Volunteers
- 27 people
- Sponsor
- Universitair Ziekenhuis Brussel
Cystic Fibrosis
Study of a Nebulised Nitric Oxide Generating Solution in Patients With Mycobacterium Abscessus
To evaluate the change in M. abscessus cfu/g in induced sputum samples from baseline to the end of treatment with RESP301 in patients with cystic fibrosis who have treatment-naïve or treatment-refractory M.
- Trial name
- NOMAB (NCT05101915)
- Testing
- RESP301
- Where
- United Kingdom
- Volunteers
- 6 people
- Sponsor
- Papworth Hospital NHS Foundation Trust
Cystic Fibrosis, Exocrine Pancreatic Insufficiency
Safety and Efficacy Study of ULTRASE® MT20 in Participants With Cystic Fibrosis (CF) and Exocrine Pancreatic Insufficiency (PI)
The purpose of this study is to assess the safety and efficacy of Ultrase® MT20 compared to placebo for the correction of fat and protein malabsorption in participants with cystic fibrosis (CF) and exocrine pancreatic…
- Trial name
- NCT00408317
- Testing
- Ultrase® MT20
- Where
- 4 sites in United States
- Volunteers
- 36 people
- Sponsor
- Forest Laboratories
Cystic Fibrosis
Tissue Bank for Pulmonary Diseases
The aim of this research study is to collect and store the specimens that are left over after patients undergo tests ordered by their physicians.
- Trial name
- NCT00546962
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- Boston Children's Hospital
Cystic Fibrosis
Breath Analysis in in Adults With Cystic Fibrosis (CF)
Exploratory comparative evaluation of exhaled breath composition in cystic fibrosis patients with age and gender-matched healthy adults in order to identify a disease-specific exhaled breath pattern as well as to gain insight…
- Trial name
- NCT02209571
- Testing
- Venous blood markers
- Where
- Switzerland
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of Zurich
Cystic Fibrosis
Safety, Tolerability and Pharmacokinetics of Tiotropium in Cystic Fibrosis Patients
Study to obtain information about the safety and tolerability of tiotropium bromide administered via the Respimat® inhalation device in pediatric (≤11 y.o.) and adolescent/adult (≥12 y.o.) cystic fibrosis (CF) patients after…
- Trial name
- NCT02172534
- Testing
- Tiotropium bromide low, Tiotropium bromide medium, Tiotropium bromide high
- Volunteers
- 113 people
- Sponsor
- Boehringer Ingelheim
Cystic Fibrosis, Pseudomonas Aeruginosa Airway Infection
Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Airway Infection
The primary objective of this program is to provide expanded access to aztreonam lysine for inhalation (AZLI) 75 mg prior to its commercial availability to patients with cystic fibrosis (CF) and chronic P.
- Trial name
- NCT00499720
- Testing
- Aztreonam Lysine for Inhalation
- Where
- 65 sites in United States, Puerto Rico
- Sponsor
- Gilead Sciences
Cystic Fibrosis
Using MRI to Observe Lung Changes in Infants With CF Compared to Infants Without CF
Our research is comparing the lungs of babies and young children with CF (cystic fibrosis) to those without CF. We are looking at the blood flow in the lungs to help doctors better understand how CF damages lungs and how to…
- Trial name
- MRIinfantCF (NCT01832519)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.